FUJIFILM Diosynth Biotechnologies vs KBI Biopharma: CDMO Comparison
Side-by-side comparison of FUJIFILM Diosynth Biotechnologies and KBI Biopharma on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- KBI Biopharma has FDA inspections on record (1); FUJIFILM Diosynth Biotechnologies does not yet appear in the FDA inspection database.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- FUJIFILM Diosynth Biotechnologies holds 12 active EMA GMP certificates; KBI Biopharma does not appear in EudraGMDP.
- FUJIFILM Diosynth Biotechnologies has stronger MHRA / UK coverage (6 compliant certificates vs 1).
On a 13-modality CDMO landscape, both FUJIFILM Diosynth Biotechnologies and KBI Biopharma qualify as AAV manufacturers; FUJIFILM Diosynth Biotechnologies carries the higher composite Signal Score for AAV programs in this comparison.
What to evaluate for AAV programs
Both FUJIFILM Diosynth Biotechnologies and KBI Biopharma qualify as AAV CDMOs. When choosing between them for AAV programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Platform & scale
Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record.
Capsid quality
Full/empty capsid ratio and aggregate control drive potency and safety. Ask about AUC, anion-exchange separation, and the analytics package for capsid characterization.
Regulatory readiness
For programs heading to BLA, a strong FDA inspection history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & timelines
AAV manufacturing slots can be constrained. Weigh the capacity signal and clinical-program load before committing.
Frequently asked: FUJIFILM Diosynth Biotechnologies vs KBI Biopharma
Which has the stronger FDA inspection record, FUJIFILM Diosynth Biotechnologies or KBI Biopharma?
Both FUJIFILM Diosynth Biotechnologies and KBI Biopharma maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. FUJIFILM Diosynth Biotechnologies has 0 FDA inspections on record; KBI Biopharma has 1.
How do FUJIFILM Diosynth Biotechnologies and KBI Biopharma compare on European GMP coverage?
FUJIFILM Diosynth Biotechnologies holds 12 active EMA GMP certificates and 6 MHRA / UK certificates. KBI Biopharma holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for AAV manufacturing — FUJIFILM Diosynth Biotechnologies or KBI Biopharma?
Both FUJIFILM Diosynth Biotechnologies and KBI Biopharma are tagged as AAV CDMOs in our directory, so both are credible options for AAV programs. The most important differentiator for AAV selection is typically platform & scale: Suspension processes scale better than adherent (HEK293) for commercial volumes. Confirm the CDMO's largest validated bioreactor scale and serotype track record. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
FUJIFILM Diosynth Biotechnologies carries a Signal Score of 84/100 and KBI Biopharma carries 84/100 — essentially tied for KBI Biopharma. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →